traumatic brain injury

This Month in Psychedelics - August 2022

Policy

Following last month’s attempt to ban five novel psychoactive substances, which was later withdrawn, the DEA announced a plan to criminalize two additional psychedelic drugs—DOI and DOC. However, shortly after the announcement the DEA backed down and communicated that it no longer intends to place these two substances in Schedule I. While this may end up being a temporary victory, it is still a big win for now.

Industry

The psychedelic industry experienced a lot of movement this month. MindMed put an end to its 18-MC for opioid addiction program and slashed a lot of their early research and development projects. atai Life Sciences also decided to narrow its focus as well, cutting three programs: DemeRx’s noribogaine program, the non-psychedelic drug N-acetylcysteine for brain injury, and Salvinorin A for depression. And finally, Mydecine is looking like it is on the verge of closing due to a lack of funding.

Research

A randomized-clinical trial found that psilocybin-assisted psychotherapy is capable of treating alcohol use disorder. The study had a fairly small sample size of only 93 patients but the effect size was large, with the patients who received psilocybin reduced their drinking by 83% within eight months of their first dose.

Meanwhile, yet another placebo-controlled study found that psilocybin microdosing did not have any significant benefits to creativity, cognition, or perception. This study also had a small sample size, with only 34 participants, but it adds to the pile of evidence accumulating against the idea that microdosing has any tangible benefits that go beyond the placebo effect.

Miscellaneous

NFL football player Aaron Rodgers opened up about how he used ayahuasca to help him with his mental health and propel him to the point where he is at now in his career as the quarterback for the Green Bay Packers. This was a pretty big admission in the world of sports, where the use of illegal drugs is a big no-no. Fortunately both his coach and the league were accepting of the news, and hopefully this is the beginning of a trend because it would be great to see even more professional athletes come forward about their experiences with illegal drugs.

However, not all athletes got off so easy. WNBA star and two-time Olympic gold medalist Brittney Griner was sentenced to nine years in a Russian prison for the possession and smuggling of cannabis oil cartridges. Since then she has appealed the conviction and is hoping to overturn the ruling, but there’s no telling how this case will play out in court.

Wrapping up this month’s recap is a video of a wild bear who helped himself to a supply of psychedelic honey and ended up incapacitated in the back of a truck. Fortunately he turned out just fine after coming down from his trip, which I’m sure he’ll remember for the rest of his life!

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Month in Psychedelics - February 2022

A lot happened in the world of psychedelics in February. A southern U.S. state legalized medical marijuana, scientists created a new way to make 5-MeO-DMT, a follow-up study found psilocybin therapy was an effective treatment for major depression for one year, zebrafish microdosed LSD, and the NFL invested $1 million into cannabinoids.

There’s a lot to get through this month, so without further ado, let’s jump into the news:

Policy

Wins

Southern states have been among the last to warm up to cannabis policy reforms, but Mississippi legalized medical marijuana for people with qualifying debilitating conditions like cancer or sickle cell disease. The law went into effect but it may still be several months before dispensaries will open.

Future

Following last month’s news about the DEA trying to criminalize five more psychedelics, a judge granted a hearing for opposition to the proposal. It will take place in May.

Industry

The recent explosion of interest surrounding 5-MeO-DMT has put a strain on the population of Sonoran Desert toads, which has been under threat of being wiped out because of their highly sought-after psychedelic venom. However, scientists may have found a solution to help conserve the species—a new way to farm 5-MeO-DMT that doesn’t involve milking toads. To make matters even better, the company behind this discovery plans to operate in the spirit of open science by supplying other companies with free samples of the substance as long as they make a commitment to open science.

Sustainable iboga is hard to find in the West, but Gabon has taken the first step toward setting up a legal distribution channel for the plant. In this model, participating villages will work alongside Gabon’s Ministry of Forests, a North American iboga therapy center operator, and the NGO Blessings of the Forest.

Money changed hands from the profit sector to a non-profit company this month as MAPS became the beneficiary of a handsome $500k donation from atai Life Sciences’ philanthropy arm, atai Impact.

Research

Published Studies

Ravers and festival-goers often refer to experiencing the dreaded “comedown” after taking MDMA, but a new study indicated that the drug itself doesn’t actually cause comedowns. Instead, factors such as the unknown purity of illicit substances, lack of rest, and becoming dehydrated can contribute to whether they occur or not.

The jury’s still out when it comes to whether microdosing is effective or just a placebo, but another trial found no evidence that microdosing LSD does anything. However, a different study found that giving microdoses of LSD to zebrafish may indicate its potential benefits for humans. As always, we need more research. But especially in the case of microdosing.

New research trials looking at using psychedelics to treat depression reported positive results. One follow-up study found that psilocybin therapy relieved major depressive disorder symptoms for up to one year in most patients. Two studies found that ketamine is capable of alleviating depression and quieting suicidal thoughts. And the first-ever clinical trial of DMT for major depressive disorder showed promise.

Cannabis is often blamed for causing people to become lazy and sit around on the couch wasting the day away. But over the last few years, many studies have found the exact opposite. Another one was added to the pile this month, as it found that consuming cannabis does not result in “amotivational syndrome.”

Future Studies

Concussions have been a big topic in the sports world for the last few years. A lot of effort is going into researching what can be done to recover from head injuries, and the NFL made big moves by investing $1 million into cannabinoid research. Two medical teams will investigate how cannabinoids affect pain management and neuroprotection.

Miscellaneous

You may recall that last year a U.S. sprinter named Sha’Carri Richardson was suspended from competing in the 2021 Summer Olympics due to a positive cannabis test. That was bad enough on its own, but this month Richardson suggested there may be a racist double standard at play after the Olympics allowed a Russian skater to compete in the 2022 Winter Olympics even after failing a drug test—for a performance enhancing drug, no less! There are some differences between the two cases, but it does seem a bit questionable, to say the least.

And last up for this recap is a reminder that although psychedelics have the potential of uncovering the truth sometimes, the insights that they give you aren’t always true. It’s tempting to fall into the mental trap of believing that everything you experience while tripping is correct, but if you or someone you know has been feeling that way lately then be sure to check out the linked article above.

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Month in Psychedelics - September 2021

September was another busy month in the world of psychedelics. Some of the highlights include Hamilton Morris ending his show and joining a notorious psychedelic company, the FDA and CDC issuing scary warnings about delta-8 THC products, Scotland decriminalizing all drugs, the looming threat that nitrous oxide might become illegal in the UK soon, and a study finding that young adults are using a lot of psychedelics during the pandemic.

Here’s a video version of this month’s recap if you’d prefer to watch the update instead:

There’s a lot to get through this month, so without further ado, let’s jump into the news:

Policy

Wins

Every month activists and politicians work feverishly toward reforming drug policies all over the world, and this month was no exception. Among some of the victories, the possession of Class A drugs is now set to be effectively decriminalized in Scotland, which means people who are caught with substances like MDMA and LSD will be given a warning instead of facing prosecution.

A recreational cannabis trial in Zurich is slated to begin in 2022. The Swiss pilot program will run for three-and-a-half years and may influence other European countries to follow suit.

Future

There are several drug policy bills and initiatives coming down the pike. Michigan has multiple efforts to decriminalize psychedelics, including Senate Bill 631, which would decriminalize the possession and use of many psychedelics across the state, and there are also local efforts to decriminalize psychedelics in Detroit, Grand Rapids, and Hazel Park.

Meanwhile, authorities in the UK are so concerned about the trash that is generated from public nitrous oxide use that they’re pushing to ban the drug outright.

Just a couple months after the suspension of runner Sha’Carri Richardson from competing in the Olympics due to a positive THC test, the World Anti-Doping Agency is going to conduct a scientific review of cannabis next year to figure out whether to continue the international ban of marijuana use by athletes.

Industry

If you haven’t already heard of him, Hamilton Morris is a very well-known figure in the world of psychedelics. He’s a research scientist, journalist, and filmmaker who gave the world the brilliant TV show Hamilton’s Pharmacopeia, which explores the chemistry, history, and cultural impact of various psychoactive drugs.

However, his show is coming to an end after three seasons, as he has been hired as a full-time consultant for COMPASS Pathways, the mental healthcare company notoriously attempting to profit off of medicalizing psilocybin.

Research

Published Studies

The annual Monitoring the Future survey looked at the recreational use of psychedelics by young people and found that it is on the rise in the United States. This increase in psychedelic exploration by U.S. college students and other young adults has risen in part because of the COVID-19 pandemic but also because psychedelics are more accepted today than they used to be.

Yale researchers found that a single dose of psilocybin can promote structural changes in the brains of mice that fight against symptoms of depression. The scientists discovered that psilocybin triggered a 10% increase in neuron size and density in the animals’ frontal cortex, which occurred within 24 hours and lasted for one month, indicating that psilocybin engendered long-lasting changes in the brain.

A first-of-its-kind study published in Psychopharmacology found that synthetic cannabinoid users experience more severe withdrawal symptoms than traditional cannabis users. During a period of abstinence, adverse side effects like insomnia, irritation, moodiness, heart palpitations, and appetite were significantly worse in the synthetic cannabis-using group.

Future Studies

Looking ahead, a study looking to treat tobacco addiction with psilocybin will receive federal funding from the National Institute on Drug Abuse, making this the first time an investigation into the potential therapeutic effects of psychedelics has received funds from the federal government since the War on Drugs began in the 1970s.

Researchers at the University of California San Francisco will determine how effective Fireside Project’s psychedelic hotline and app actually are at helping people navigate their psychedelic experiences.

A study has been given the fitting name of “Desire Project” because it will look at treating female hypoactive sexual desire disorder with MDMA-assisted psychotherapy.

The first participant in a psilocybin trial for a rare headache disorder named short-lasting unilateral neuralgiform headache attacks (SUNHA) received an initial low dose of the drug to kick off the study. The disorder involves short, incredibly painful headaches that can occur many times a day, and there are not currently any approved treatments for it. This proof-of-concept Phase 1B trial will enroll 12 patients and is expected to generate results in early 2022.

The Heroic Hearts Project UK announced a study with Imperial College London that will investigate the physiological and psychological effects of psilocybin on veterans with traumatic brain injury. The researchers hope to add additional weight to the mostly anecdotal body of evidence suggesting that the drug may help people heal from this sort of ailment.

Harm Reduction

The FDA and CDC issued warnings to consumers about potential risks involving delta-8 THC, a relatively new psychoactive cannabinoid that has grown in popularity due to its widespread legality but remains essentially unregulated at this time. Apparently there has been a significant increase in reported adverse health effects from people using this drug.

However, before you go ahead and toss any of these products you may already own out of the window, it may be helpful to know that it’s not like people are getting poisoned. In fact, it’s far more likely that they are unintentionally getting high after using delta-8 THC because of misunderstandings, bad labeling, and a lack of experience.

Miscellaneous

Following up on the case involving the death of unarmed 23 year-old Elijah McClain after being administered a fatal dose of ketamine by first responders in Aurora, Colorado back in 2019, the police officers and paramedics involved have all been charged with criminally-negligent homicide and manslaughter.

New forensic science techniques have been developed that will enable law enforcement agencies to recover human DNA from the surfaces of pills and capsules, which authorities hope will help them identify who has handled illicit substances that are seized by police. This means that anyone touching an MDMA capsule or ecstasy pill for as little as 15 seconds during their production, assembly,  or distribution could be identified using this new technology.

A new Hulu show called Nine Perfect Strangers is the latest mainstream production to feature psychedelic use, and apparently it’s fairly problematic. I haven’t watched it yet myself but from what I’ve read, the plot involves a wellness guru who runs a retreat where she gives attendees microdoses of psilocybin without their knowledge or consent. It should go without saying that this is not cool and dosing others without them knowing it is unethical and potentially extremely dangerous. I’m going to reserve any judgment on this show until I make time to check it out myself, but now you’ll have at least a little bit of an idea about it in case anyone you know mentions it to you.

There is an update on the story involving Jake Angeli, AKA the “QAnon Shaman” who participated in the storming of the U.S. Capitol on January 6th of this year. Earlier this month Angeli plead guilty to one of the most serious of his six charges and could face a maximum of 20 years in prison, although his lack of a criminal record will likely mean he will serve much less time.

The ongoing global labor shortage means that employers around the world are finding it difficult to hire employees, and screening them for drug use is making things even harder. As a result, many companies are getting rid of drug tests in an effort to attract more applicants, fill vacancies, and keep their existing workers.

Hiring wasn’t the only thing that was impacted during the pandemic—it turns out that cannabis arrests in the U.S. declined significantly during 2020, according to data released by the FBI. Still, more than 350k marijuana-related arrests were made last year, mostly in states that have not yet decriminalized or legalized possession and use of the plant.

Wrapping up this month’s recap is a story out of Canada where a group of drug users and drug policy reformers are so fed up with the drug war that they are suing the government. The non-profit organization is known as the Canadian Association of People Who Use Drugs and they are claiming that the Canadian government is responsible for fatal overdoses because it requires users to go to the illegal market and purchase unsafe drugs from a toxic drug supply.

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Week in Psychedelics - 6.4.21

ThisWeekinPsychedelics.png

Cannabis

  • Bill To Federally Legalize Marijuana Reintroduced In Congress As Senate Prepares Separate Measure (Marijuana Moment)

  • Amazon Now Supports Federal Cannabis Legalization (Forbes)

  • Nevada: Lawmakers Approve Measure to Regulate Cannabis Consumption Lounges (NORML)

  • Idaho Marijuana Activists Launch Limited Legalization Campaign For 2022 Ballot (Marijuana Moment)

  • Medical cannabis has ‘96% chance of seizure reduction’ in childhood epilepsy (Cannabis Health News)

  • Tennessee Governor Signs Bill To Expand State’s Limited Medical Marijuana Program (Marijuana Moment)

  • Colorado: Senate Lawmakers Advance Measure Amending State’s Medical Cannabis Access Law (NORML)

  • Mississippi Lawmakers Hold Medical Marijuana Hearing After Court Overturns Voter-Approved Law (Marijuana Moment)

  • As legal marijuana booms, people push for justice for those impacted by war on drugs (ABC News)

  • Illinois: Lawmakers Approve Equity Measure to Award Over 100 New Dispensary Licenses (NORML)

Magic Mushrooms

  • Want to Measure the Magic in Your Mushrooms? You Can Now Test Psilocybin Potency at Home (DoubleBlind)

  • Psilocybin May Reduce Suicidal Thoughts in Terminally Ill Patients, Suggests New Study (Lucid News)

  • Psychedelic Mushroom Shops Reach The Americas (Forbes)

  • Psilocybin-assisted Therapy for Mental Health: A New Paradigm? (Volteface)

  • COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers (Psilocybin Alpha)

  • The Psilocybin vs. Escitalopram Trial – Part 2 (Psychedelic Science Review)

MDMA

  • One Man Took 40,000 Ecstasy Pills In Nine Years – This Is What Happened To Him (IFLScience)

5-MeO-DMT

  • Studying Ibogaine and 5-MeO-DMT for Traumatic Brain Injuries: Interview with Amber Capone of VETS (Psychedelic Times)

San Pedro

  • Microdosing Huachuma: Sacred Cactus of the Andes (EntheoNation)

Iboga

  • MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research (Psilocybin Alpha)

Salvia Divinorum

  • Salvia Flowers: Cultivation and Consumption (DoubleBlind)

Ketamine

  • Ketamine a game changer in treating eating disorders (Toronto Sun)

Miscellaneous

  • California Senate Approves Bill To Legalize Possession Of Psychedelics Like Psilocybin And LSD (Marijuana Moment)

  • Psychedelics Patent Claim Raises Questions From Researchers Who Say They Did It First (VICE)

  • Texas Bills To Expand Medical Marijuana Program And Require Psychedelics Study Head To Governor’s Desk (Marijuana Moment)

  • New York Bill Would Create State-Sponsored Psychedelics Research Institute (Marijuana Moment)

  • The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’ (The Guardian)

  • NIH: It’s time to make your mark on the renaissance of medicinal psychedelics (STAT)

  • Andrew Yang Proposes Legal Psychedelic Therapies For Veterans In NYC Mayoral Plan (Marijuana Moment)

  • New Zealand scientists explore medical benefits of psychedelic drugs (Newshub)

  • Can Psychedelics Help Heal Moral Injury? (Psychedelics Today)

  • Psychedelics: A New Fountain of Youth? (Psychedelic Science Review)

  • Pandemic Drug Use and the Cartel (Reality Sandwich)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Month in Psychedelics - May 2021

ThisMonthinPsychedelics.png

May was yet another busy one for psychedelic news, with plenty of drug policy reform progress, industry developments, groundbreaking research, and a couple controversial events taking place. In this month’s update we’ll dive into these topics and much more.

Here is a slimmed-down video recap version that is available for those who prefer an easier-to-digest option:

There’s a lot to get through this month, so without further ado, let’s jump into the news:

Drug Policy

Wins

Two states made huge progress on cannabis reform. First, Montana’s governor signed a bill to implement the recreational marijuana program that voters approved last November. Retail sales for adults 21 and older will begin in January of next year. And continuing an emerging pattern of Southern states revamping cannabis laws, Alabama’s governor signed legislation to legalize medical marijuana in the state. The country is turning more and more green every month!

A few other bills made huge progress as well but have not crossed the finish line yet: an attempt to decriminalize psychedelics in California, legislation that would enable Texas to conduct psychedelic research, a cannabis legalization effort in Minnesota, and Switzerland is getting closer to legalizing marijuana as well.

Losses

Some bills hit a wall though. In Mexico lawmakers failed to legalize cannabis ahead of a Supreme Court deadline, Aspen’s city council chose not to decriminalize psychedelics, drug possession is now a misdemeanor in Washington State, Mississippi’s Supreme Court overturned a medical marijuana legalization ballot that voters approved last November, Colorado and New York banned delta-8 THC, China banned synthetic cannabinoids, and Amsterdam and a London borough banned nitrous oxide.

Future


Looking ahead, Republicans in the U.S. are pushing for the federal legalization of cannabis to ensure individual liberty, so legal weed in America is looking more and more like becoming a possibility sometime soon.

Industry

An NHL star’s brain trauma led him to found a psychedelic startup company, legal cannabis states have generated nearly $8 billion in tax revenue since recreational sales launched, Champignon Brands changed its name to Braxia Scientific, and MindMed announced Project Angie, the company’s attempt to treat pain with psychedelics.

Research

The results from MAPS’ Phase 3 trial of MDMA-assisted therapy for PTSD are in, and things are looking promising for this novel form of treatment. Out of 90 participants who enrolled in the study, the group which received MDMA during therapy experienced a more significant reduction in the severity of their PTSD symptoms compared to the placebo-controlled group. In fact, two months after treatment 67% of people in the MDMA group no longer qualified for a PTSD diagnosis whereas only 32% of the placebo group did. These results are promising and lend credence to the idea that MDMA will be legally available for medical use within the next couple years.

Other research studies found that psilocybin may be able to treat migraine headaches, how LSD opens the doors of perception, that frequent cannabis consumers are more physically active than non-users, and that actual drug education is far better than the government’s typical approach of “just say no.” In addition, the U.S. federal government announced a new standard THC dose to be used in cannabis research.

Miscellaneous

Causing a bit of a stir in the global psychedelic community, a publication known as Psychedelic Invest published a list of the 100 most influential people in psychedelics ranking candidates based on the following factors: social reach, scientific accomplishments, legislative initiatives, and value creation/contribution. The list was criticized for its lack of diversity, which prompted a public response acknowledging the fact the publication failed to prioritize the inclusion of a diverse group of people when creating it. In today’s political climate it’s no wonder that the publication of a list like this was heavily criticized, but the constructive reaction from Psychedelic Invest indicates that the publication is willing to learn from its mistake.

A new cannabis product generated an uproar on social media. Dubbed Canna Bumps, this unique cannabis concentrate looked kind of like cocaine and was intended to be snorted by consumers. Needless to say, it caught a lot of flack from industry insiders and judgmental marijuana smokers alike. Claiming that it would hurt the movement to legalize cannabis on a federal level, enough people complained that the product was quickly pulled from the market.

Now me personally, I can see how a product like this could be used by drug warriors to hurt the effort to reform drug laws, but I’m also in full support of people consuming their preferred drugs by whatever route of administration they see fit. Hopefully one of these days a snortable marijuana product will be available for consumers, but until then things are just going to keep moving a bit more slowly.

Wrapping up this month’s recap is an update on where Decriminalize Nature stands when it comes to peyote. You may recall that some Native American groups around the country have spoken out against the drug decriminalization movement including peyote in its recommendations for drugs to be decriminalized, and now Decrim Nature has officially announced a peyote conservation plan that is intended to work in tandem with the conservation strategy that is already underway.

Under this resolution, peyote found in its natural habit would be available only for indigenous communities and poaching would continue to be penalized, but the personal cultivation of peyote by non-indigenous people would be decriminalized, which would hopefully address the existing demand for the cacti and help assist with the ongoing conservation effort.

That’s all for this month’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this month’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.